Welcome to our dedicated page for IGC Pharma news (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma stock.
IGC Pharma, Inc. (NYSE American: IGC) is a clinical-stage biotechnology company whose news flow centers on Alzheimer's disease drug development, pharmaceutical cannabinoids, and AI-enabled research. The company regularly reports updates on its lead asset, IGC-AD1, a cannabinoid-based therapy in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia, along with progress across its broader pipeline and AI platforms.
News about IGC Pharma often includes clinical trial milestones, such as enrollment progress and expansion of the CALMA study to new sites. For example, the company has highlighted reaching key enrollment thresholds and adding hybrid and virtual clinical sites like Dominion Medical Associates, part of Lightship's network, to improve access for patients in underserved and rural communities. These announcements provide insight into trial design, recruitment strategies, and geographic reach.
Investors and observers can also expect corporate and financial updates, including capital raises under an effective Form S-3 shelf registration statement, strategic divestitures of non-core assets, and changes to the company's fiscal year-end to align with the calendar year. SEC-reported events, such as registered direct offerings and asset sale closings, are frequently accompanied by press releases that explain how proceeds and transactions relate to IGC Pharma's clinical and research priorities.
Another recurring theme in IGC Pharma's news is AI and intellectual property developments. The company reports advances in its MINT-AD platform for Alzheimer's risk stratification and early detection, recognition from the National Institute on Aging for AI code quality, and new or allowed patents that expand its pharmaceutical cannabinoid portfolio, including microdose-based treatments for stuttering and Tourette's Syndrome.
In addition, IGC Pharma issues news on community and educational initiatives, such as sponsoring a caregiver-focused Alzheimer's book authored by neuropsychology experts. Together, these news items provide a view into the company's clinical progress, AI research, regulatory positioning, capital strategy, and engagement with the Alzheimer's community. Readers interested in IGC's stock and operations can use this news feed to follow trial updates, financing events, patent activity, and strategic decisions over time.
IGC Pharma announced promising preclinical results for its Alzheimer's therapeutic candidate, TGR-63. In mouse models, TGR-63 demonstrated a significant reduction in amyloid plaques—78% in the cortex and 85% in the hippocampus. This indicates potential for slowing or reversing Alzheimer's progression. TGR-63's effectiveness in disrupting amyloid beta aggregates and promoting neuronal viability was observed in cell cultures. The company plans to begin Phase 1 clinical trials for TGR-63 by 2025. IGC Pharma continues to develop its robust pipeline of Alzheimer's treatments, with a focus on leveraging AI for early disease detection and trial optimization.
IGC Pharma, a clinical-stage pharmaceutical company, released its financial results for the fiscal year ending March 31, 2024. The company reported a revenue increase to $1.3 million, primarily from its Life Sciences segment. There was a notable decrease in SG&A expenses by 21% to $6.7 million. However, R&D expenses rose by 9% to $3.8 million due to ongoing clinical trials. The company had a net loss of $13 million, reflecting a $3.3 million one-time impairment. Significant achievements include positive interim results from the Phase 2 trial of IGC-AD1, promising preclinical data for TGR-63, and securing three new patents. Additionally, IGC signed a cooperation agreement with the University of Los Andes for AI research in pharmaceuticals. The company also raised $6 million through share purchases and secured a $12 million credit line to support expanded operations.
IGC Pharma announced that CEO Ram Mukunda and CCO Claudia Grimaldi will participate in a fireside chat hosted by Ascendiant Capital Markets on June 27, 2024, at 12:00 pm ET. They will discuss recent achievements and upcoming milestones. IGC Pharma focuses on developing treatments for Alzheimer's disease with a pipeline that includes five drug candidates. Notably, IGC-AD1 is in Phase 2 clinical trials targeting agitation in dementia associated with Alzheimer's, while other candidates like TGR-63, IGC-M3, and IGC-1C are in preclinical stages. The company also leverages AI for Alzheimer's research.
IGC Pharma announced a new study published in the European Society of Medicine Journal examining the impact of CYP2C9 genetic polymorphisms on the pharmacokinetics of delta-9-tetrahydrocannabinol (THC) in Alzheimer's patients. The study, conducted with Puerto Rican participants, revealed significant variations in THC metabolism among different genetic profiles, underscoring the importance of personalized medicine.
IGC is currently in Phase 2 trials of IGC-AD1, a THC-based drug candidate aimed at treating agitation in Alzheimer's patients. The research aligns with IGC's commitment to include underrepresented populations and develop innovative treatments. CEO Ram Mukunda and lead scientist Dr. Jagadeesh S. Rao highlighted the study's importance for personalized dosing strategies in Alzheimer's care.
IGC Pharma has commenced patient enrollment at Neurostudies in Port Charlotte, Florida, for its Phase 2 clinical trial of IGC-AD1, a THC-based formulation aimed at treating agitation in Alzheimer's patients. The trial, involving 146 participants, will assess the efficacy of IGC-AD1, which targets neuroinflammation and neurotransmitter imbalances. Neurostudies, led by Dr. Liliana Montoya and Dr. George Li, brings over 20 years of clinical research experience.
Two patients were enrolled in May 2024, marking a significant milestone for IGC Pharma. The company has 11 more trial sites under contract in the U.S. and Canada. Ram Mukunda, CEO of IGC Pharma, emphasized the company's commitment to advancing Alzheimer's therapies. IGC Pharma's pipeline includes five drug candidates aimed at different aspects of Alzheimer's pathology.
IGC Pharma will participate in the BIO International Convention at the San Diego Convention Center from June 3-6, 2024. The company intends to explore partnerships and strategic opportunities for its Alzheimer's disease therapies, including cannabinoid-based IGC-AD1 and amyloid-beta targeting TGR-63. IGC-AD1 is in Phase 2 clinical trials for agitation in dementia associated with Alzheimer’s, while TGR-63 aims to disrupt Alzheimer’s progression by targeting Aβ plaques. IGC Pharma's pipeline also includes IGC-M3 and IGC-1C, both in preclinical stages, focusing on Aβ plaques and tau protein, respectively. Additionally, the company leverages AI for research in Alzheimer's.
Summary not available.
Summary not available.
Summary not available.
Summary not available.